Year: 2010
Type: article
Abstract: For monitoring effi cacy of sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy, data obtained from studies of children seemed inadequate.High prevalence of triple and quadruple mutants in the dihydropteroate synthase and dihydrofolate reductase genes of Plasmodium falciparum parasites contrasts with the effi cacy of sulfadoxine/pyrimethamine in reducing low birthweights and placental infection rates.In light of this discrepancy, emphasis on using molecular markers for monitoring effi cacy of intermittent preventive treatment dur-ing pregnancy appears questionable.The World Health Organization recently proposed conducting in vivo studies in pregnant women to evaluate molecular markers for detecting resistance precociously.Other possible alternative strategies are considered.M alaria during pregnancy is a major cause of anemia and maternal death and one of the main causes of low birthweight (1,2).Consequently, the World Health Organization (WHO) recommends protection for women during pregnancy.Until recently, prevention consisted of weekly chemoprophylaxis with either chloroquine or sulfadoxine/ pyrimethamine.Because of poor patient compliance with prophylaxis and increasing resistance of parasite strains to chloroquine, administration of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine/pyrimethamine Sulfadoxine/Pyrimethamine Intermittent Preventive Treatment for Malaria during Pregnancy
Source: Emerging infectious diseases
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1988942657
